KYNB Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Kyntra Bio, Inc. had $6.4M of revenue in fiscal 2025, down 78.3% on the year before. Over five years, revenue changed β48.4% a year on average.
Last close Β· Oct 23, 2026
$4.58
12.3%Hi! I read Kyntra Bio, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β78.3%
No. Sales fell 78.3% last year.
Does it make a profit?
2,848.6%
Yes. It keeps 2,848.6% of every sale as profit.
Does profit turn into cash?
β74.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
0.1x
One share costs 0.1 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Kyntra Bio, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 9, 2026
Monday Β· in 14 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 11, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 16, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 10, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 11, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 12, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 19, 2025 | Q4 '24 | Time not announced | 8-K β |
| Nov 12, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Kyntra Bio, Inc. had $6.4M of revenue in fiscal 2025, down 78.3% on the year before. Over five years, revenue changed β48.4% a year on average. Its operating margin was β712.7%, down 204.9Β pts: of every 100 in sales, about β713 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Kyntra Bio, Inc. made $183M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$4.8M in fiscal 2025, β74.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Kyntra Bio, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $405M | $422M | $203M | $50.5M | $89.0M |
| Interest coverage | β268.4x | β209.0x | β39.9x | β18.2x | β5.2x |
| Current ratio | 2.1x | 1.8x | 1.5x | 1.5x | 3.4x |
| Quick ratio | 2.0x | 1.7x | 1.4x | 1.5x | 3.3x |
| Total assets | $774M | $610M | $424M | $215M | $120M |
| Total liabilities | $545M | $612M | $586M | $398M | $115M |
| Shareholders' equity | $209M | β$21.4M | β$204M | β$226M | β$30.0M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Kyntra Bio, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 3 / 7 | 2 / 7 | 2 / 8 | 2 / 8 | 1 / 8 | 1 / 8 | 3 / 8 | 4 / 8 |
| Accruals ratio | β13.9% | β7.9% | β1.2% | 0.2% | β32.2% | β26.0% | β21.3% | 6.0% | 28.3% | 112.7% |
| Altman Z'' | β0.89 | 3.26 | 2.68 | 2.59 | 0.45 | β5.32 | β9.32 | β17.90 | β32.09 | β45.53 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $183M | $131M | $213M | $257M | $176M | $235M | $141M | $46.8M | $29.6M | $6.4M |
| Gross profit | β | β | β | $255M | $167M | $222M | $120M | $42.8M | $14.1M | $5.9M |
| Research and development | $187M | $197M | $236M | $209M | $253M | $387M | $297M | $266M | $95.7M | $23.5M |
| Operating income | β$50.0M | β$117M | β$86.7M | β$89.3M | β$192M | β$289M | β$301M | β$323M | β$150M | β$45.9M |
| Interest expense | $10.7M | $9.7M | $11.0M | $2.9M | $2.4M | $1.1M | $1.4M | $8.1M | $8.2M | $8.8M |
| Pretax income | β$58.1M | β$121M | β$86.1M | β$76.6M | β$189M | β$291M | β$295M | β$323M | β$153M | β$58.3M |
| Income tax | β$0.1M | $0.3M | $0.3M | $0.3M | $0.4M | $0.3M | $0.4M | β$0.3M | β$0.3M | β$0.1M |
| Net income | β$58.1M | β$121M | β$86.4M | β$77.0M | β$189M | β$290M | β$294M | β$284M | β$47.6M | $183M |
| Diluted EPS | β$0.93 | β$1.66 | β$1.03 | β$0.89 | β$2.11 | β$3.14 | β$3.14 | β$2.92 | β$11.89 | $45.37 |
| Diluted shares | 0.06B | 0.07B | 0.08B | 0.09B | 0.09B | 0.09B | 0.09B | 0.10B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | $7.1M | β$66.5M | β$76.1M | β$78.7M | $81.6M | β$82.2M | β$146M | β$315M | β$138M | β$4.8M |
| Capital expenditure | $1.3M | $8.5M | $8.0M | $5.8M | $4.0M | $5.2M | $3.7M | $2.5M | $0.3M | $0.0M |
| Free cash flow | $5.9M | β$75.0M | β$84.2M | β$84.5M | $77.6M | β$87.4M | β$150M | β$318M | β$138M | β$4.8M |
| Depreciation and amortization | $6.0M | $6.1M | $6.6M | $11.1M | $11.7M | $10.2M | $10.0M | $9.5M | $2.7M | $0.7M |
| Stock-based compensation | $32.1M | $37.5M | $52.1M | $66.3M | $72.7M | $71.2M | $65.6M | $50.8M | $25.2M | $6.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $253M | $736M | $621M | $534M | $687M | $405M | $422M | $203M | $50.5M | $89.0M |
| Finance lease liabilities | β | β | β | $50.0M | $37.7M | $0.0M | $0.2M | $0.1M | β | β |
| Current assets | $267M | $749M | $690M | $702M | $755M | $474M | $493M | $332M | $197M | $99.1M |
| Current liabilities | $65.1M | $86.0M | $89.0M | $103M | $163M | $225M | $274M | $218M | $133M | $29.2M |
| Inventory | β | β | $0.0M | $6.9M | $16.5M | $31.0M | $40.4M | $17.2M | $3.2M | $3.7M |
| Property and equipment, net | $124M | $129M | $127M | $42.7M | $33.6M | $28.3M | $20.6M | $4.8M | $0.0M | β |
| Total assets | $470M | $899M | $881M | $857M | $827M | $774M | $610M | $424M | $215M | $120M |
| Total liabilities | $294M | $351M | $352M | $322M | $385M | $545M | $612M | $586M | $398M | $115M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β |
| Shareholders' equity | $156M | $528M | $509M | $516M | $422M | $209M | β$21.4M | β$204M | β$226M | β$30.0M |
| Margins | ||||||||||
| Gross margin | β | β | β | 99.6% | 95.0% | 94.5% | 85.6% | 91.5% | 47.5% | 91.4% |
| Operating margin | β27.3% | β89.5% | β40.7% | β34.8% | β108.8% | β122.6% | β213.9% | β689.5% | β507.8% | β712.7% |
| EBITDA margin | β24.0% | β84.9% | β37.6% | β30.5% | β102.2% | β118.3% | β206.8% | β669.2% | β498.8% | β701.6% |
| Net margin | β31.7% | β92.3% | β40.6% | β30.0% | β107.4% | β123.3% | β208.7% | β607.3% | β160.6% | 2,848.6% |
| FCF margin | 3.2% | β57.3% | β39.5% | β32.9% | 44.0% | β37.2% | β106.4% | β678.5% | β466.8% | β74.7% |
| Returns | ||||||||||
| Return on capital employed | β12.4% | β14.4% | β11.0% | β11.8% | β28.9% | β52.6% | β89.5% | β156.8% | β185.2% | β50.8% |
| Return on equity | β37.3% | β35.3% | β16.7% | β15.0% | β40.3% | β91.9% | β312.9% | β | β | β |
| Return on assets | β12.4% | β17.7% | β9.7% | β8.9% | β22.5% | β36.2% | β42.4% | β55.0% | β14.9% | 109.8% |
| Return on tangible equity | β37.3% | β22.9% | β17.0% | β14.9% | β44.8% | β138.7% | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β28.5% | 62.6% | 20.5% | β31.3% | 33.5% | β40.2% | β66.7% | β36.7% | β78.3% |
| FCF growth | β | β1,381.0% | β | β | β | β212.6% | β | β | β | β |
| Share count change | β | 16.3% | 15.2% | 3.1% | 3.7% | 2.8% | 1.3% | 4.0% | β95.9% | 1.0% |
| Financial health | ||||||||||
| Interest coverage | β4.7x | β12.1x | β7.9x | β31.1x | β79.9x | β268.4x | β209.0x | β39.9x | β18.2x | β5.2x |
| Current ratio | 4.1x | 8.7x | 7.8x | 6.8x | 4.6x | 2.1x | 1.8x | 1.5x | 1.5x | 3.4x |
| Quick ratio | 4.1x | 8.7x | 7.8x | 6.8x | 4.5x | 2.0x | 1.7x | 1.4x | 1.5x | 3.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.7% | 6.5% | 3.8% | 2.2% | 2.3% | 2.2% | 2.7% | 5.4% | 0.9% | 0.6% |
| Stock comp / revenue | 17.5% | 28.7% | 24.5% | 25.8% | 41.2% | 30.2% | 46.6% | 108.5% | 85.1% | 102.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 3.0 | 2.0 | 2.0 | 2.0 | 1.0 | 1.0 | 3.0 | 4.0 |
| Altman Z'' | β0.9 | 3.3 | 2.7 | 2.6 | 0.4 | β5.3 | β9.3 | β17.9 | β32.1 | β45.5 |
| Accruals ratio | β13.9% | β7.9% | β1.2% | 0.2% | β32.2% | β26.0% | β21.3% | 6.0% | 28.3% | 112.7% |
Source: SEC EDGAR XBRL filings (CIK 0000921299). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
